TiGenix Lead Compound Cx601 Efficient in Treating CD Patients’ Perianal Fistulas

TiGenix Lead Compound Cx601 Efficient in Treating CD Patients’ Perianal Fistulas
TiGenix, a leading biopharmaceutical company developing therapeutics based on adult stem cells, recently announced the results of the Phase III ADMIRE-CD clinical trial, testing the company’s lead compound Cx601 on Crohn’s disease patients with complex perianal fistulas. Crohn’s disease is a type of inflammatory bowel disease (IBD) and is characterized by inflammation of the digestive tract, with

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *